Importance Each year in the US, approximately 100 000 people are treated for cervical
precancer, 14 000 people are diagnosed with cervical cancer, and 4000 die of cervical …

Background Human papillomavirus (HPV) vaccination programmes were first implemented
in several countries worldwide in 2007. We did a systematic review and meta-analysis to …

Background The efficacy and effectiveness of the quadrivalent human papillomavirus (HPV)
vaccine in preventing high-grade cervical lesions have been shown. However, data to …

Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …

Background: Human papillomavirus (HPV) vaccination was introduced in 2006 for females
and in 2011 for males. Objective: To estimate vaccine impact and effectiveness against …

Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …

Human papillomavirus (HPV) vaccines work by preventing infections prior to natural
exposure. Thus, it is likely more effective at younger ages, and it is important to understand …

Importance Case reports have suggested a link between human papillomavirus (HPV)
vaccination and development of multiple sclerosis and other demyelinating diseases …

Background In clinical trials, vaccines against human papillomavirus (HPV) have been
highly effective against HPV16-or HPV18-associated cervical lesions. The quadrivalent HPV …

Human papillomavirus (HPV) types 16/18, included in HPV vaccines, contribute to the
majority of cervical cancer, and a substantial proportion of cervical intraepithelial neoplasia …